Mobile

Immunogenicity and Safety of the Investigational Inactivated, Split-Virion Influenza Vaccine 15 µg Administered by the Intradermal Route in Comparison with the Intramuscular Reference Vaccine Vaxigrip...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-001219-39

Immunogenicity and Safety of the Investigational Inactivated, Split-Virion Influenza Vaccine 15 µg Administered by the Intradermal Route in Comparison with the Intramuscular Reference Vaccine Vaxigrip® in 50 to 59 Years old Adults

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

• To demonstrate that the ID investigational vaccine is at least as immunogenic as the IM reference vaccine in terms of geometric mean titer (GMT) after vaccination. • If non-inferiority is demonstrated, to demonstrate that the ID investigational vaccine induces a better immunogenicity than the IM reference vaccine in terms of seroprotection rate after vaccination.

Critère d'inclusion

  • Vaccination of adults subjects aged 50 to 59 years with inactivated, split-virion influenza vaccine administered by the intradermal route using Vaxigrip® as IM reference vaccine

Liens